Related Experiment Video
Updated: Sep 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Treating elevated lipids. Does it make a difference?
Insights
Lipid-lowering therapy significantly reduces coronary heart disease (CHD) event risk by approximately 30%. High-risk individuals experience the greatest absolute benefit from cholesterol-lowering medications.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Clinical trials demonstrate that lipid-modifying therapy reduces coronary heart disease (CHD) risk.
- Treatment decisions require balancing costs and benefits.
Purpose of the Study:
- To evaluate the cardiovascular benefits of cholesterol-lowering medications.
- Assessed evidence from primary and secondary prevention studies.
Main Methods:
- Systematic review of clinical trials.
- Analysis of primary and secondary prevention studies.
Main Results:
- Cholesterol-lowering treatment reduces relative risk of major CHD events by ~30%.
- Highest benefit observed in high-risk populations due to greater absolute risk reduction.
- Moderate-risk individuals require more treatment to prevent one event compared to high-risk individuals.
Conclusions:
- Treating hypercholesterolemia offers significant cardiovascular benefits.
- Lipid-lowering therapy is most impactful in high-risk patient groups.
- The benefit in moderate-risk groups is comparable to primary stroke prevention via hypertension management.
Background:
There is now abundant evidence from clinical trials that treatment with lipid modifying therapy will decrease the risk of coronary heart disease (CHD). The decision to treat a patient, whether with advice on lifestyle modification or with drug therapy, needs to be based on consideration of costs versus benefits.
Objective:
To assess the evidence from primary and secondary prevention studies for cardiovascular benefit of cholesterol lowering medication.
Discussion:
Treating hypercholesterolaemia reduces the relative risk of major CHD events by about 30%. The greatest benefit of lipid lowering treatment is in the high risk group. This group shows the greatest reduction in absolute risk and therefore a 'smaller number to treat' to prevent one major CHD event. In the moderate risk group three times as many individuals require treatment to prevent one major CHD event. However, this corresponds to the benefit in primary prevention of stroke by treating mild-moderate hypertension in middle aged men.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management

